Payment overview · 2025
General Payments
$534.97
22 reported records · 9 companies
Healthcare provider profile · identity verified
Alan Gross, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · POUGHKEEPSIE, NY · NPI 1194745869
Verified facts
What the public records show
CMS Open Payments records show Alan Gross, M.D. received $534.97 in general payments during 2025 across 22 reported records.
GlaxoSmithKline, LLC. accounted for 31.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 14 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Jardiance, Trelegy Ellipta.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 523 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 30 claims for Jardiance by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 33 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $165.71 | 31.0% | 8 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $123.52 | 23.1% | 4 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $74.45 | 13.9% | 3 | 2025 |
| Verona Pharma, Inc. | Unresolved — no canonical attribution shown | $51.64 | 9.7% | 2 | 2025 |
| Inspire Medical Systems, Inc. | Unresolved — no canonical attribution shown | $36.34 | 6.8% | 1 | 2025 |
| ANI Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $26.56 | 5.0% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $24.36 | 4.5% | 1 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $18.38 | 3.4% | 1 | 2025 |
| Phadia US Inc. | Unresolved — no canonical attribution shown | $14.01 | 2.6% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $534.97 | 22 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| NUCALA Normalized: nucala |
Biological | GlaxoSmithKline, LLC. | $140.73 | 7 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $123.52 | 4 | 2025 |
Source payment records
|
|||||
| Ohtuvayre Normalized: ohtuvayre |
Drug | Verona Pharma, Inc. | $51.64 | 2 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $50.86 | 2 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $50.86 | 2 | 2025 |
Source payment records
|
|||||
| INSPIRE Normalized: inspire |
Device | Inspire Medical Systems, Inc. | $36.34 | 1 | 2025 |
Source payment records
|
|||||
| PURIFIED CORTROPHIN GEL Normalized: purified cortrophin gel |
Drug | ANI Pharmaceuticals, Inc. | $26.56 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $24.98 | 1 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $24.36 | 1 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $24.36 | 1 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $24.36 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Lilly USA, LLC | $23.59 | 1 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $18.38 | 1 | 2025 |
Source payment records
|
|||||
| ImmunoCAP Normalized: immunocap |
Device | Phadia US Inc. | $14.01 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 30 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 523 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
523 | 98 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
30 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
33 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 523 | 98 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 396 | 126 |
| Atorvastatin Calcium | Atorvastatin Calcium | 350 | 100 |
| Lisinopril | Lisinopril | 190 | 52 |
| Amlodipine Besylate | Amlodipine Besylate | 184 | 52 |
| Levothyroxine Sodium | Levothyroxine Sodium | 158 | 42 |
| Montelukast Sodium | Montelukast Sodium | 146 | 39 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 145 | 45 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 143 | 33 |
| Losartan Potassium | Losartan Potassium | 139 | 44 |
| Gabapentin | Gabapentin | 138 | 32 |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 136 | 25 |
| Omeprazole | Omeprazole | 132 | 37 |
| Prednisone | Prednisone | 110 | 45 |
| Hydrochlorothiazide | Hydrochlorothiazide | 101 | 32 |
| Incruse Ellipta | Umeclidinium Bromide | 95 | 16 |
| Metformin Hcl | Metformin Hcl | 94 | 26 |
| Zolpidem Tartrate | Zolpidem Tartrate | 83 | 15 |
| Furosemide | Furosemide | 70 | 22 |
| Metoprolol Succinate | Metoprolol Succinate | 70 | 22 |
| Trazodone Hcl | Trazodone Hcl | 67 | 14 |
| Clonazepam | Clonazepam | 66 | 16 |
| Spiriva Respimat | Tiotropium Bromide | 64 | 12 |
| Symbicort | Budesonide/Formoterol Fumarate | 62 | 13 |
| Alprazolam | Alprazolam | 59 | 12 |
| Januvia | Sitagliptin Phosphate | 59 | 13 |
| Allopurinol | Allopurinol | 57 | 16 |
| Roflumilast | Roflumilast | 56 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 56 | 14 |
| Tamsulosin Hcl | Tamsulosin Hcl | 52 | 15 |
| Pantoprazole Sodium | Pantoprazole Sodium | 51 | 19 |
| Fluticasone Propionate | Fluticasone Propionate | 49 | 18 |
| Ventolin Hfa | Albuterol Sulfate | 48 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 46 | 11 |
| Pravastatin Sodium | Pravastatin Sodium | 46 | 13 |
| Simvastatin | Simvastatin | 46 | 13 |
| Breo Ellipta | Fluticasone/Vilanterol | 45 | suppressed |
| Azithromycin | Azithromycin | 44 | 39 |
| Stiolto Respimat | Tiotropium Br/Olodaterol Hcl | 44 | suppressed |
| Glipizide Er | Glipizide | 43 | 11 |
| Escitalopram Oxalate | Escitalopram Oxalate | 42 | suppressed |
| Theophylline Er | Theophylline Anhydrous | 40 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 37 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 37 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 35 | suppressed |
| Potassium Chloride | Potassium Chloride | 35 | suppressed |
| Atenolol | Atenolol | 34 | suppressed |
| Carvedilol | Carvedilol | 34 | 11 |
| Eliquis | Apixaban | 33 | suppressed |
| Meloxicam | Meloxicam | 33 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 31 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 31 | 14 |
| Jardiance | Empagliflozin | 30 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 30 | suppressed |
| Metoprolol Tartrate | Metoprolol Tartrate | 30 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 29 | suppressed |
| Ezetimibe | Ezetimibe | 29 | suppressed |
| Xarelto | Rivaroxaban | 28 | suppressed |
| Lorazepam | Lorazepam | 26 | suppressed |
| Lovastatin | Lovastatin | 25 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 24 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 22 | suppressed |
| Famotidine | Famotidine | 22 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 21 | 16 |
| Ozempic | Semaglutide | 21 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 21 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 20 | suppressed |
| Glimepiride | Glimepiride | 20 | suppressed |
| Naproxen | Naproxen | 20 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 19 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 19 | 12 |
| Synthroid | Levothyroxine Sodium | 19 | suppressed |
| Chlorthalidone | Chlorthalidone | 18 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 18 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 18 | suppressed |
| Ramipril | Ramipril | 18 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 17 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 17 | suppressed |
| Levalbuterol Tartrate Hfa | Levalbuterol Tartrate | 16 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 16 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 15 | suppressed |
| Risperidone | Risperidone | 15 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 15 | suppressed |
| Amoxicillin | Amoxicillin | 14 | 11 |
| Azelastine Hcl | Azelastine Hcl | 14 | suppressed |
| Cephalexin | Cephalexin | 14 | 14 |
| Glipizide | Glipizide | 14 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 14 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 14 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 14 | suppressed |
| Serevent Diskus | Salmeterol Xinafoate | 14 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 14 | suppressed |
| Valsartan | Valsartan | 14 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 13 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 13 | suppressed |
| Ibuprofen | Ibuprofen | 13 | suppressed |
| Arnuity Ellipta | Fluticasone Furoate | 12 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 12 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 12 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 12 | suppressed |
| Levofloxacin | Levofloxacin | 12 | 11 |
| Memantine Hcl | Memantine Hcl | 12 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 12 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 12 | suppressed |
| Epinephrine | Epinephrine | 11 | suppressed |
| Gemfibrozil | Gemfibrozil | 11 | suppressed |
| Glassia | Alpha-1-Proteinase Inhibitor | 11 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 11 | suppressed |
| Lansoprazole | Lansoprazole | 11 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 11 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $534.97 · 22 records | GlaxoSmithKline, LLC. | ABRYSVO, CAPVAXIVE, COMIRNATY, Cologuard Collection Kit, INSPIRE, ImmunoCAP, JARDIANCE, MOUNJARO, NUCALA, Ohtuvayre, PREVNAR 20, PURIFIED CORTROPHIN GEL, TRELEGY ELLIPTA, ZEPBOUND | 3 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Jardiance play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with GlaxoSmithKline, LLC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error